Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
Open Access
- 1 October 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 138 (10), 2168-2173
- https://doi.org/10.1016/j.jid.2018.04.019
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior AdalimumabPLOS ONE, 2015
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsThe Lancet, 2015
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical RecommendationsThe AAPS Journal, 2014
- Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasisThe Journal of Dermatology, 2012
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)Journal of Dermatological Science, 2011
- Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapyBritish Journal of Dermatology, 2011
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJournal of the American Academy of Dermatology, 2006
- Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialThe Lancet, 2005